Top Page
bioAffinity Technologies, Inc.
(NASDAQ:BIAF)
bioAffinity Technologies, Inc. (BIAF) vs. SPDR S&P 500 ETF (SPY)
bioAffinity Technologies, Inc. Business Overview & Revenue Model
bioAffinity Technologies, Inc. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.36M | 2.53M | 4.80K | 0.00 | 0.00 |
| Gross Profit | 3.38M | 791.62K | 4.34K | -4.82K | -22.24K |
| EBITDA | -8.33M | -7.63M | -5.61M | -2.20M | -6.86M |
| Net Income | -9.04M | -7.94M | -8.15M | -6.33M | -7.27M |
Balance Sheet | |||||
| Total Assets | 6.51M | 8.22M | 12.18M | 1.45M | 145.60K |
| Cash, Cash Equivalents and Short-Term Investments | 1.11M | 2.82M | 11.41M | 1.36M | 83.11K |
| Total Debt | 1.50M | 1.58M | 251.75K | 11.36M | 10.01M |
| Total Liabilities | 3.91M | 3.37M | 1.14M | 17.24M | 15.22M |
| Stockholders Equity | 2.60M | 4.86M | 11.04M | -15.79M | -15.07M |
Cash Flow | |||||
| Free Cash Flow | -7.34M | -6.06M | -4.29M | -2.05M | -2.21M |
| Operating Cash Flow | -7.26M | -6.04M | -4.07M | -2.05M | -2.21M |
| Investing Cash Flow | -79.08K | -2.21M | -219.99K | 0.00 | -2.89K |
| Financing Cash Flow | 5.63M | -344.98K | 14.34M | 3.33M | 1.72M |
bioAffinity Technologies, Inc. Technical Analysis
bioAffinity Technologies, Inc. Risk Analysis
bioAffinity Technologies, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $21.49M | ― | -25.29% | ― | 26.67% | 44.02% | |
61 Neutral | $13.13M | ― | -126.34% | ― | 3.87% | 91.76% | |
55 Neutral | $7.59M | ― | -809.29% | ― | ― | ― | |
50 Neutral | $9.88M | ― | -290.85% | ― | 78.40% | 22.41% | |
46 Neutral | C$201.68M | -3.28 | -23.14% | 1.87% | 20.75% | -0.36% | |
43 Neutral | $12.62M | ― | 77.20% | ― | -4.02% | -6.60% | |
41 Neutral | $11.64M | ― | -127.82% | ― | -24.04% | 84.11% |
bioAffinity Technologies, Inc. Corporate Events
On July 23, 2025, bioAffinity Technologies announced a case study where their CyPath® Lung test successfully identified a Stage 1A neuroendocrine tumor in a patient’s lung, which was missed by other diagnostic tools. This highlights the test’s importance as an adjunct to traditional imaging and diagnostic methods, offering clarity in cases where other tools are inconclusive, thus potentially improving patient outcomes through early detection and treatment.
The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On July 22, 2025, bioAffinity Technologies announced that it received a notification of allowance from the Canadian Patent Office for a patent application related to methods of predicting lung cancer using flow cytometry. This patent, titled ‘System and Method for Determining Lung Health,’ protects the use of specific antibodies and porphyrin TCPP to label cell populations in sputum and utilize flow cytometry to detect lung cancer cells. The patent strengthens the company’s international protection for its diagnostic platform, particularly its flagship test, CyPath® Lung. This development is significant as lung cancer is the leading cause of cancer deaths in Canada, and the patent is expected to expand bioAffinity’s market presence in the region, enhancing shareholder value and highlighting the company’s focus on early cancer detection.
The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On July 15, 2025, bioAffinity Technologies announced it received a notification of allowance from the China National Intellectual Property Administration for a patent related to predicting lung cancer likelihood using flow cytometry. This patent positions the company to expand its proprietary diagnostic platform in China, a significant market with a high prevalence of smokers and lung cancer cases. The patent protects the use of specific antibodies and porphyrin TCPP in labeling cell populations in sputum to detect lung cancer cells, enhancing the company’s global patent portfolio and supporting its strategy to build long-term shareholder value through innovation and early cancer detection.
The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On May 27, 2025, bioAffinity Technologies, Inc. received a notice from Nasdaq indicating non-compliance with the stockholders’ equity requirement of $2,500,000, as their equity was reported at $1,439,404 as of March 31, 2025. The company plans to submit a compliance plan by July 11, 2025, to address this issue and maintain its listing on the Nasdaq Capital Market. The notification does not immediately affect the company’s listing, and they are exploring options to regain compliance, although acceptance of the plan by Nasdaq is not guaranteed. This notice is separate from a previous deficiency related to the minimum bid price requirement.
The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On May 22, 2025, bioAffinity Technologies, Inc. entered into an At-The-Market Issuance Sales Agreement with WallachBeth Capital LLC to facilitate the sale of its common stock through an ‘at the market offering’ program. This agreement allows the company to sell shares directly on the Nasdaq Capital Market or other trading platforms, with WallachBeth acting as the sales agent. The agreement provides flexibility in terms of the number of shares sold and the timing, while also allowing for termination by either party under certain conditions. The arrangement is expected to enhance the company’s financial flexibility and market presence.
The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
bioAffinity Technologies, Inc. has announced plans for its 2025 Annual Meeting of Stockholders, which will take place on July 25, 2025. The company has set the record date for determining stockholders entitled to vote at the meeting as May 29, 2025. Due to the meeting being scheduled more than 30 days after the previous year’s meeting, revised deadlines for stockholder proposals have been provided. Proposals under Rule 14a-8 must be submitted by May 26, 2025, while notices for director nominations must comply with Rule 14a-19 by May 29, 2025.
The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On May 7, 2025, bioAffinity Technologies, Inc. completed a public offering of common stock and warrants, raising approximately $3.2 million in gross proceeds. The company plans to use the funds for working capital and general corporate purposes. The offering included agreements that restrict the issuance of additional shares for a specified period, which may impact the company’s market activities and shareholder interests.